Inhibiting Cell Cycle Kinases in Cancer Therapy

Frontiers in Medicinal Chemistry

Volumn 6, Issue , 2012, Pages 152-186

  de Cárcer, Guillermo ^a   de Castro, Ignacio Pérez ^a   Malumbres, Marcos ^a  

^a Structural Biology and Biocomputing Programme   (Spain)

Author keywords

apoptosis; Aurora; BUB kinases; cancer target; Cell cycle; checkpoint; cyclin dependent kinase; mitosis; NEK; PLK; serine threonine kinase

Indexed keywords

EID: 84919724584     PISSN: 15672042     EISSN: 18755763     Source Type: Book Series    
DOI: 10.2174/9781608054640113060009     Document Type: Chapter

References (266)

1. Nurse, P. Genetic control of cell size at cell division in yeast. Nature, 1975, 256, 547-551.
2. Nigg, E. A. Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol, 2001, 2, 21-32.
3. Nalepa, G.; Rolfe, M.; Harper, J. W. Drug discovery in the ubiquitin-proteasome system. Nat Rev Drug Discov, 2006, 5, 596-613.
4. Gutierrez, G. J.; Ronai, Z. Ubiquitin and SUMO systems in the regulation of mitotic checkpoints. Trends Biochem Sci, 2006, 31, 324-332.
5. Nakayama, K. I.; Nakayama, K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer, 2006, 6, 369-381.
6. Sansam, C. G.; Roberts, C. W. Epigenetics and cancer: altered chromatin remodeling via Snf5 loss leads to aberrant cell cycle regulation. Cell Cycle, 2006, 5, 621-624.
7. Malumbres, M.; Barbacid, M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer, 2001, 1, 222-231.
8. Massague, J. G1 cell-cycle control and cancer. Nature, 2004, 432, 298-306.
9. Sherr, C. J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res, 2000, 60, 3689-3695.
10. Ortega, S.; Malumbres, M.; Barbacid, M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta, 2002, 1602, 73-87.
11. Hanahan, Douglas; Weinberg, Robert A. The Hallmarks of Cancer. Cell, 2000, 100, 57-70.
12. Malumbres, M.; Barbacid, M. Mammalian cyclin-dependent kinases. Trends Biochem Sci, 2005, 30, 630-641.
13. Evans, Tom; Rosenthal, Eric T.; Youngblom, Jim; Distel, Dan; Hunt, Tim. Cyclin: A protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division. Cell, 1983, 33, 389-396.
14. Lukas, J.; Bohr, V. A.; Halazonetis, T. D. Cellular responses to DNA damage: current state of the field and review of the 52nd Benzon Symposium. DNA Repair (Amst), 2006, 5, 591-601.
15. Bartek, J.; Lukas, C.; Lukas, J. Checking on DNA damage in S phase. Nat Rev Mol Cell Biol, 2004, 5, 792-804.
16. Kastan, M. B.; Bartek, J. Cell-cycle checkpoints and cancer. Nature, 2004, 432, 316-323.
17. Kops, Geert J. P. L.; Weaver, Beth A. A.; Cleveland, Don W. On the road to cancer: Aneuploidy abd the mitotic checkpoint. Nature Reviews Cancer, 2005, 5, 773-785.
18. Diffley, J. F. Regulation of early events in chromosome replication. Curr Biol, 2004, 14, R778-786.
19. Sherr, C. J.; Roberts, J. M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev, 1999, 13, 1501-1512.
20. Kim, J. M.; Masai, H. Genetic dissection of mammalian Cdc7 kinase: cell cycle and developmental roles. Cell Cycle, 2004, 3, 300-304.
21. Yoshizawa-Sugata, N.; Ishii, A.; Taniyama, C.; Matsui, E.; Arai, K.; Masai, H. A second human Dbf4/ASK-related protein, Drf1/ASKL1, is required for efficient progression of S and M phases. J Biol Chem, 2005, 280, 13062-13070.
22. Malumbres, M.; Carnero, A. Cell cycle deregulation: a common motif in cancer. Prog Cell Cycle Res, 2003, 5, 5-18.
23. Sotillo, R.; Dubus, P.; Martin, J.; De La Cueva, E.; Ortega, S.; Malumbres, M.; Barbacid, M. Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors. Embo J, 2001, 20, 6637-6647.
24. Sotillo, R.; Garcia, J. F.; Ortega, S.; Martin, J.; Dubus, P.; Barbacid, M.; Malumbres, M. Invasive melanoma in Cdk4-targeted mice. Proc Natl Acad Sci U S A, 2001, 98, 13312-13317.
25. Sotillo, R.; Renner, O.; Dubus, P.; Ruiz-Cabello, J.; Martin-Caballero, J.; Barbacid, M.; Carnero, A.; Malumbres, M. Cooperation between Cdk4 and p27kip1 in tumor development: a preclinical model to evaluate cell cycle inhibitors with therapeutic activity. Cancer Res, 2005, 65, 3846-3852.
26. Malumbres, M.; Sotillo, R.; Santamaria, D.; Galan, J.; Cerezo, A.; Ortega, S.; Dubus, P.; Barbacid, M. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell, 2004, 118, 493-504.
27. Malumbres, Marcos; Barbacid, Mariano. Is Cyclin D1-CDK4 kinase a bona fide cancer target? Cancer Cell, 2006, 9, 2-4.
28. Malumbres, M. Revisiting the "Cdk-centric" view of the mammalian cell cycle. Cell Cycle, 2005, 4, 206-210.
29. Senderowicz, Adrian M.; Sausville, Edward A. Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators. J Natl Cancer Inst, 2000, 92, 376-387.
30. Sausville, Edward A. Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends in Molecular Medicine, 2002, 8, S32-S37.
31. Senderowicz, A. M. Small-molecule cyclin-dependent kinase modulators. Oncogene, 2003, 22, 6609-6620.
32. Shapiro, G. I. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol, 2006, 24, 1770-1783.
33. Fischer, P. M.; Endicott, J.; Meijer, L. Cyclin-dependent kinase inhibitors. Prog Cell Cycle Res, 2003, 5, 235-248.
34. Sausville, E. A. Cell cycle regulatory kinase modulators: interim progress and issues. Curr Top Med Chem, 2005, 5, 1109-1117.
35. Fuse, E.; Kuwabara, T.; Sparreboom, A.; Sausville, E. A.; Figg, W. D. Review of UCN-01 development: a lesson in the importance of clinical pharmacology. J Clin Pharmacol, 2005, 45, 394-403.
36. Knockaert, M.; Greengard, P.; Meijer, L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci, 2002, 23, 417-425.
37. Fry, David W.; Harvey, Patricia J.; Keller, Paul R.; Elliott, William L.; Meade, Maryanne; Trachet, Erin; Albassam, Mudher; Zheng, Xianxian; Leopold, Wilbur R.; Pryer, Nancy K.; Toogood, Peter L. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther, 2004, 3, 1427-1438.
38. Beattie, John F.; Breault, Gloria A.; Ellston, Rebecca P. A.; Green, Stephen; Jewsbury, Philip J.; Midgley, Catherine J.; Naven, Russell T.; Minshull, Claire A.; Pauptit, Richard A.; Tucker, Julie A.; Pease, J. Elizabeth. Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 1: identification and optimisation of substituted 4,6-Bis anilino pyrimidines. Bioorganic & Medicinal Chemistry Letters, 2003, 13, 2955-2960.
39. Soni, Rajeev; O'reilly, Terence; Furet, Pascal; Muller, Lionel; Stephan, Christine; Zumstein-Mecker, Sabine; Fretz, Heinz; Fabbro, Doriano; Chaudhuri, Bhabatosh. Selective In Vivo and In Vitro Effects of a Small Molecule Inhibitor of Cyclin-Dependent Kinase 4. J Natl Cancer Inst, 2001, 93, 436-446.
40. Carini, David J.; Kaltenbach, Robert F.; Liu, Jie; Benfield, Pamela A.; Boylan, John; Boisclair, Michael; Brizuela, Leonardo; Burton, Catherine R.; Cox, Sarah. Identification of selective inhibitors of cyclin dependent kinase 4. Bioorganic & Medicinal Chemistry Letters, 2001, 11, 2209-2211.
41. Honma, T.; Hayashi, K.; Aoyama, T.; Hashimoto, N.; Machida, T.; Fukasawa, K.; Iwama, T.; Ikeura, C.; Ikuta, M.; Suzuki-Takahashi, I.; Iwasawa, Y.; Hayama, T.; Nishimura, S.; Morishima, H. Structure-Based Generation of a New Class of Potent Cdk4 Inhibitors: New de Novo Design Strategy and Library Design. J. Med. Chem., 2001, 44, 4615-4627.
42. Zhu, G.; Conner, S. E.; Zhou, X.; Shih, C.; Li, T.; Anderson, B. D.; Brooks, H. B.; Campbell, R. M.; Considine, E.; Dempsey, J. A.; Faul, M. M.; Ogg, C.; Patel, B.; Schultz, R. M.; Spencer, C. D.; Teicher, B.; Watkins, S. A. Synthesis, Structure-Activity Relationship, and Biological Studies of Indolocarbazoles as Potent Cyclin D1-CDK4 Inhibitors. J. Med. Chem., 2003, 46, 2027-2030.
43. Fry, David W.; Bedford, David C.; Harvey, Patricia H.; Fritsch, Alexandra; Keller, Paul R.; Wu, Zhipei; Dobrusin, Ellen; Leopold, Wilbur R.; Fattaey, Ali; Garrett, Michelle D. Cell Cycle and Biochemical Effects of PD 0183812. A Potent Inhibitor of the Cyclin D-dependent Kinases CDK4 and CDK6. J. Biol. Chem., 2001, 276, 16617-16623.
44. Toogood, P. L.; Harvey, P. J.; Repine, J. T.; Sheehan, D. J.; Vanderwel, S. N.; Zhou, H.; Keller, P. R.; Mcnamara, D. J.; Sherry, D.; Zhu, T.; Brodfuehrer, J.; Choi, C.; Barvian, M. R.; Fry, D. W. Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6. J. Med. Chem., 2005, 48, 2388-2406.
45. Matsumoto, Y.; Maller, J. L. A centrosomal localization signal in cyclin E required for Cdk2-independent S phase entry. Science, 2004, 306, 885-888.
46. Hinchcliffe, E. H.; Sluder, G. Two for two: Cdk2 and its role in centrosome doubling. Oncogene, 2002, 21, 6154-6160.
47. Duensing, A.; Liu, Y.; Tseng, M.; Malumbres, M.; Barbacid, M.; Duensing, S. Cyclin-dependent kinase 2 is dispensable for normal centrosome duplication but required for oncogene-induced centrosome overduplication. Oncogene, 2006, 25, 2943-2949.
48. Lingle, W. L.; Salisbury, J. L. The role of the centrosome in the development of malignant tumors. Curr Top Dev Biol, 2000, 49, 313-329.
49. Brinkley, Bill R. Managing the centrosome numbers game: from chaos to stability in cancer cell division. Trends in Cell Biology, 2001, 11, 18-21.
50. Vulpetti, A.; Pevarello, P. An analysis of the binding modes of ATP-competitive CDK2 inhibitors as revealed by X-ray structures of protein-inhibitor complexes. Curr Med Chem Anticancer Agents, 2005, 5, 561-573.
51. Steven J. Mcclue, David Blake, Rosemary Clarke, Angela Cowan, Lorna Cummings, Peter M. Fischer, Mairi Mackenzie, Jean Melville, Kevin Stewart, Shudong Wang, Nikolai Zhelev, Daniella Zheleva, David P. Lane. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). International Journal of Cancer, 2002, 102, 463-468.
52. Misra, R. N.; Xiao, H. Y; Kim, K. S.; Lu, S.; Han, W. C.; Barbosa, S. A.; Hunt, J. T.; Rawlins, D. B.; Shan, W.; Ahmed, S. Z.; Qian, L.; Chen, B. C.; Zhao, R.; Bednarz, M. S.; Kellar, K. A.; Mulheron, J. G.; Batorsky, R.; Roongta, U.; Kamath, A.; Marathe, P.; Ranadive, S. A.; Sack, J. S.; Tokarski, J. S.; Pavletich, N. P.; Lee, F. Y. F.; Webster, K. R.; Kimball, S. D. N-(Cycloalkylamino)acyl-2-aminothiazole Inhibitors of Cyclin-Dependent Kinase 2. N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a Highly Efficacious and Selective Antitumor Agent. J. Med. Chem., 2004, 47, 1719-1728.
53. Siemeister, G.; Briem, H.; Brumby, T.; Haberey, M.; Hess-Stumpp, H.; Jautelat, R.; Kruger, M.; Lucking, U.; Reichel, A.; Schafer, M.; Bosslet, K. In Proc. Am. Assoc. Cancer Res, 2004; Vol. 45, Abst 829..
54. Bach, S.; Knockaert, M.; Reinhardt, J.; Lozach, O.; Schmitt, S.; Baratte, B.; Koken, M.; Coburn, S. P.; Tang, L.; Jiang, T.; Liang, D. C.; Galons, H.; Dierick, J. F.; Pinna, L. A.; Meggio, F.; Totzke, F.; Schachtele, C.; Lerman, A. S.; Carnero, A.; Wan, Y.; Gray, N.; Meijer, L. Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem, 2005, 280, 31208-31219.
55. Kuo, G. H.; Deangelis, A.; Emanuel, S.; Wang, A.; Zhang, Y.; Connolly, P. J.; Chen, X.; Gruninger, R. H.; Rugg, C.; Fuentes-Pesquera, A.; Middleton, S. A.; Jolliffe, L.; Murray, W. V. Synthesis and Identification of [1,3,5]Triazine-pyridine Biheteroaryl as a Novel Series of Potent Cyclin-Dependent Kinase Inhibitors. J. Med. Chem., 2005, 48, 4535-4546.
56. Ortega, S.; Prieto, I.; Odajima, J.; Martin, A.; Dubus, P.; Sotillo, R.; Barbero, J. L.; Malumbres, M.; Barbacid, M. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet, 2003, 35, 25-31.
57. Berthet, C.; Aleem, E.; Coppola, V.; Tessarollo, L.; Kaldis, P. Cdk2 knockout mice are viable. Curr Biol, 2003, 13, 1775-1785.
58. Tetsu, O.; Mccormick, F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell, 2003, 3, 233-245.
59. Martin, A.; Odajima, J.; Hunt, S. L.; Dubus, P.; Ortega, S.; Malumbres, M.; Barbacid, M. Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27(Kip1) and p21(Cip1). Cancer Cell, 2005, 7, 591-598.
60. Aleem, E.; Kiyokawa, H.; Kaldis, P. Cdc2-cyclin E complexes regulate the G1/S phase transition. Nat Cell Biol, 2005, 7, 831-836.
61. Ren, Shengjun; Rollins, Barrett J. Cyclin C/Cdk3 Promotes Rb-Dependent G0 Exit. Cell, 2004, 117, 239-251.
62. Hofmann, F.; Livingston, D. M. Differential effects of cdk2 and cdk3 on the control of pRb and E2F function during G1 exit. Genes Dev, 1996, 10, 851-861.
63. Ye, Xin; Zhu, Cihui; Harper, J. Wade. A premature-termination mutation in the Mus musculus cyclin-dependent kinase 3 gene. PNAS, 2001, 98, 1682-1686.
64. Bartkova, J.; Zemanova, M.; Bartek, J. Expression of CDK7/CAK in normal and tumor cells of diverse histogenesis, cell-cycle position and differentiation. Int J Cancer, 1996, 66, 732-737.
65. Loyer, P.; Trembley, J. H.; Katona, R.; Kidd, V. J.; Lahti, J. M. Role of CDK/cyclin complexes in transcription and RNA splicing. Cell Signal, 2005, 17, 1033-1051.
66. Petretti, C.; Savoian, M.; Montembault, E.; Glover, D. M.; Prigent, C.; Giet, R. The PITSLRE/CDK11p58 protein kinase promotes centrosome maturation and bipolar spindle formation. EMBO Rep, 2006, 7, 418-424.
67. Tsuji, T.; Ficarro, S. B.; Jiang, W. Essential Role of Phosphorylation of MCM2 by Cdc7/Dbf4 in the Initiation of DNA Replication in Mammalian Cells. Mol Biol Cell, 2006, 17.
68. Masai, H.; Arai, K. Cdc7 kinase complex: a key regulator in the initiation of DNA replication. J Cell Physiol, 2002, 190, 287-296.
69. Kim, J. M.; Nakao, K.; Nakamura, K.; Saito, I.; Katsuki, M.; Arai, K.; Masai, H. Inactivation of Cdc7 kinase in mouse ES cells results in S-phase arrest and p53-dependent cell death. Embo J, 2002, 21, 2168-2179.
70. Fluge, O.; Bruland, O.; Akslen, L. A.; Lillehaug, J. R.; Varhaug, J. E. Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid, 2006, 16, 161-175.
71. Montagnoli, Alessia; Tenca, Pierluigi; Sola, Francesco; Carpani, Daniela; Brotherton, Deborah; Albanese, Clara; Santocanale, Corrado. Cdc7 Inhibition Reveals a p53-Dependent Replication Checkpoint That Is Defective in Cancer Cells. Cancer Res, 2004, 64, 7110-7116.
72. Kim, J. M.; Takemoto, N.; Arai, K.; Masai, H. Hypomorphic mutation in an essential cell-cycle kinase causes growth retardation and impaired spermatogenesis. Embo J, 2003, 22, 5260-5272.
73. Mcgowan, C. H.; Russell, P. The DNA damage response: sensing and signaling. Curr Opin Cell Biol, 2004, 16, 629-633.
74. Kurz, E. U.; Lees-Miller, S. P. DNA damage-induced activation of ATM and ATM-dependent signaling pathways. DNA Repair (Amst), 2004, 3, 889-900.
75. Kawabe, T. G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther, 2004, 3, 513-519.
76. Abraham, R. T. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev, 2001, 15, 2177-2196.
77. Shiloh, Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer, 2003, 3, 155-168.
78. Zhou, B. B.; Anderson, H. J.; Roberge, M. Targeting DNA checkpoint kinases in cancer therapy. Cancer Biol Ther, 2003, 2, S16-22.
79. Menoyo, Anna; Alazzouzi, Hafid; Espin, Eloi; Armengol, Manel; Yamamoto, Hiroyuki; Schwartz, Simo, Jr. Somatic Mutations in the DNA Damage-Response Genes ATR and CHK1 in Sporadic Stomach Tumors with Microsatellite Instability. Cancer Res, 2001, 61, 7727-7730.
80. Smith, L.; Liu, S. J.; Goodrich, L.; Jacobson, D.; Degnin, C.; Bentley, N.; Carr, A.; Flaggs, G.; Keegan, K.; Hoekstra, M.; Thayer, M. J. Duplication of ATR inhibits MyoD, induces aneuploidy and eliminates radiation-induced G1 arrest. Nat Genet, 1998, 19, 39-46.
81. Brown, E. J.; Baltimore, D. ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev, 2000, 14, 397-402.
82. Cortez, D.; Guntuku, S.; Qin, J.; Elledge, S. J. ATR and ATRIP: partners in checkpoint signaling. Science, 2001, 294, 1713-1716.
83. Cliby, W. A.; Roberts, C. J.; Cimprich, K. A.; Stringer, C. M.; Lamb, J. R.; Schreiber, S. L.; Friend, S. H. Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints. Embo J, 1998, 17, 159-169.
84. Fukuchi, Kunihiko; Watanabe, Hiroyuki; Tomoyasu, Shigeru; Ichimura, Sachiko; Tatsumi, Kouichi; Gomi, Kunihide. Phosphatidylinositol 3-kinase inhibitors, Wortmannin or LY294002, inhibited accumulation of p21 protein after [gamma]-irradiation by stabilization of the protein. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, 2000, 1496, 207-220.
85. Bohm, Lothar; Roos, Wynand Paul; Serafin, Antonio Mendes. Inhibition of DNA repair by Pentoxifylline and related methylxanthine derivatives. Toxicology, 2003, 193, 153-160.
86. Sarkaria, Jann N.; Busby, Ericka C.; Tibbetts, Randal S.; Roos, Pia; Taya, Yoichi; Karnitz, Larry M.; Abraham, Robert T. Inhibition of ATM and ATR Kinase Activities by the Radiosensitizing Agent, Caffeine. Cancer Res, 1999, 59, 4375-4382.
87. Hickson, I.; Zhao, Y.; Richardson, C. J.; Green, S. J.; Martin, N. M.; Orr, A. I.; Reaper, P. M.; Jackson, S. P.; Curtin, N. J.; Smith, G. C. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res, 2004, 64, 9152-9159.
88. Li, Y.; Yang, D. Q. The ATM inhibitor KU-55933 suppresses cell proliferation and induces apoptosis by blocking Akt in cancer cells with overactivated Akt. Mol Cancer Ther, 2010, 9, 113-125.
89. Rainey, M. D.; Charlton, M. E.; Stanton, R. V.; Kastan, M. B. Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. Cancer Res, 2008, 68, 7466-7474.
90. Bartek, Jiri; Lukas, Jiri. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell, 2003, 3, 421-429.
91. Takai, Hiroyuki; Tominaga, Kaoru; Motoyama, Noboru; Minamishima, Yohji A.; Nagahama, Hiroyasu; Tsukiyama, Tadasuke; Ikeda, Kyoji; Nakayama, Keiko; Nakanishi, Makoto; Nakayama, Kei-Ichi. Aberrant cell cycle checkpoint function and early embryonic death in Chk1-/-mice. Genes Dev., 2000, 14, 1439-1447.
92. Liu, Qinghua; Guntuku, Saritha; Cui, Xian-Shu; Matsuoka, Shuhei; Cortez, David; Tamai, Katsuyuki; Luo, Guangbin; Carattini-Rivera, Sandra; Demayo, Francisco; Bradley, Allan; Donehower, Larry A.; Elledge, Stephen J. Chk1 is an essential kinase that is regulated by Atr and required for the G2/M DNA damage checkpoint. Genes Dev., 2000, 14, 1448-1459.
93. Chen, Zehan; Xiao, Zhan; Chen, Jun; Ng, Shi-Chung; Sowin, Thomas; Sham, Hing; Rosenberg, Saul; Fesik, Steve; Zhang, Haiying. Human Chk1 Expression Is Dispensable for Somatic Cell Death and Critical for Sustaining G2 DNA Damage Checkpoint. Mol Cancer Ther, 2003, 2, 543-548.
94. Vassileva, Vessela; Millar, Anna; Briollais, Laurent; Chapman, William; Bapat, Bharati. Genes Involved in DNA Repair Are Mutational Targets in Endometrial Cancers with Microsatellite Instability. Cancer Res, 2002, 62, 4095-4099.
95. Ahn, J.; Urist, M.; Prives, C. The Chk2 protein kinase. DNA Repair (Amst), 2004, 3, 1039-1047.
96. Bell, Daphne W.; Varley, Jennifer M.; Szydlo, Tara E.; Kang, Deborah H.; Wahrer, Doke C.; Nbsp; R; Shannon, Kristen E.; Lubratovich, Marcie; Verselis, Sigitas J.; Isselbacher, Kurt J.; Fraumeni, Joseph F.; Birch, Jillian M.; Li, Frederick P.; Garber, Judy E.; Haber, Daniel A. Heterozygous Germ Line hCHK2 Mutations in Li-Fraumeni Syndrome. Science, 1999, 286, 2528-2531.
97. Sodha, N.; Bullock, S.; Taylor, R.; Mitchell, G.; Guertl-Lackner, B.; Williams, R. D.; Bevan, S.; Bishop, K.; Mcguire, S.; Houlston, R.S; Eeles, R.A. CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumours. British Journal Of Cancer, 2002, 87, 1445-1448.
98. Schutte, M.; Seal, S.; Barfoot, R.; Meijers-Heijboer, H.; Wasielewski, M.; Evans, D.G.; Eccles, D.; Meijers, C.; Lohman, F.; Klijn, J.; Van Den Ouweland, A.; Futreal, P.A.; Nathanson, K.L.; Weber, B.L.; Easton, D.F.; Stratton, M.R.; Rahman, N. Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. American Journal Of Human Genetics, 2003, 72, 1023-1028.
99. Dong, Xiangyang; Wang, Liang; Taniguchi, Ken; Wang, Xianshu; Cunningham, Julie M.; Mcdonnell, Shannon K.; Qian, Chiping; Marks, Angela F.; Slager, Susan L.; Peterson, Brett J.; Smith, David I.; Cheville, John C.; Blute, Michael L.; Jacobsen, Steve J.; Schaid, Daniel J.; Tindall, Donald J.; Thibodeau, Stephen N.; Liu, Wanguo.. Mutations in CHEK2 associated with prostate cancer risk. American Journal Of Human Genetics, 2003, 72, 270-280.
100. Jack, Melissa T.; Woo, Richard A.; Hirao, Atsushi; Cheung, Alison; Mak, Tak W.; Lee, Patrick W. K. Chk2 is dispensable for p53-mediated G1 arrest but is required for a latent p53-mediated apoptotic response. PNAS, 2002, 99, 9825-9829.
101. Sielecki, T. M.; Boylan, J. F.; Benfield, P. A.; Trainor, G. L. Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation. J Med Chem, 2000, 43, 1-18.
102. Kohn, Ethan A.; Yoo, Carolyn J.; Eastman, Alan. The Protein Kinase C Inhibitor Go6976 Is a Potent Inhibitor of DNA Damage-induced S and G2 Cell Cycle Checkpoints. Cancer Res, 2003, 63, 31-35.
103. Jackson, Jeffrey R.; Gilmartin, Aidan; Imburgia, Christina; Winkler, James D.; Marshall, Lisa A.; Roshak, Amy. An Indolocarbazole Inhibitor of Human Checkpoint Kinase (Chk1) Abrogates Cell Cycle Arrest Caused by DNA Damage. Cancer Res, 2000, 60, 566-572.
104. Eastman, Alan; Kohn, Ethan A.; Brown, Mary Kay; Rathman, Joerg; Livingstone, Mark; Blank, David H.; Gribble, Gordon W. A Novel Indolocarbazole, ICP-1, Abrogates DNA Damage-induced Cell Cycle Arrest and Enhances Cytotoxicity: Similarities and Differences to the Cell Cycle Checkpoint Abrogator UCN-01. Mol Cancer Ther, 2002, 1, 1067-1078.
105. Suganuma, Masashi; Kawabe, Takumi; Hori, Haruna; Funabiki, Takahiko; Okamoto, Takashi. Sensitization of Cancer Cells to DNA Damage-induced Cell Death by Specific Cell Cycle G2 Checkpoint Abrogation. Cancer Res, 1999, 59, 5887-5891.
106. Sharma, Vasudha; Tepe, Jetze J. Potent inhibition of checkpoint kinase activity by a hymenialdisine-derived indoloazepine. Bioorganic & Medicinal Chemistry Letters, 2004, 14, 4319-4321.
107. Ashwell, S.; Zabludoff, S. DNA damage detection and repair pathways--recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin Cancer Res, 2008, 14, 4032-4037.
108. Teng, M.; Zhu, J.; Johnson, M. D.; Chen, P.; Kornmann, J.; Chen, E.; Blasina, A.; Register, J.; Anderes, K.; Rogers, C.; Deng, Y.; Ninkovic, S.; Grant, S.; Hu, Q.; Lundgren, K.; Peng, Z.; Kania, R. S. Structure-based design and synthesis of (5-arylamino-2H-pyrazol-3-yl)-biphenyl-2',4'-diols as novel and potent human CHK1 inhibitors. J Med Chem, 2007, 50, 5253-5256.
109. Sorensen, Claus Storgaard; Syljuasen, Randi G.; Falck, Jacob; Schroeder, Tine; Ronnstrand, Lars; Khanna, Kum Kum; Zhou, Bin-Bing; Bartek, Jiri; Lukas, Jiri. Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell, 2003, 3, 247-258.
110. Jobson, A. G.; Cardellina, J. H., 2nd; Scudiero, D.; Kondapaka, S.; Zhang, H.; Kim, H.; Shoemaker, R.; Pommier, Y. Identification of a Bis-guanylhydrazone [4,4'-Diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of Chk2 kinase. Mol Pharmacol, 2007, 72, 876-884.
111. Williams, Michael; Jarvis, Michael F. Adenosine antagonists as potential therapeutic agents. Pharmacology Biochemistry and Behavior, 1988, 29, 433-441.
112. Jin, P.; Gu, Y.; Morgan, D. O. Role of inhibitory CDC2 phosphorylation in radiation-induced G2 arrest in human cells. J. Cell Biol., 1996, 134, 963-970.
113. Heald, Rebecca; Mcloughlin, Michael; Mckeon, Frank. Human wee1 maintains mitotic timing by protecting the nucleus from cytoplasmically activated cdc2 kinase. Cell, 1993, 74, 463-474.
114. Park, Misoon; Chae, Hee-Don; Yun, Jeanho; Jung, Moonsu; Kim, Yeon-Soo; Kim, Sung-Ho; Han, Moon Hi; Shin, Deug Y. Constitutive Activation of Cyclin B1-associated cdc2 Kinase Overrides p53-mediated G2-M Arrest. Cancer Res, 2000, 60, 542-545.
115. Leach, S. D.; Scatena, C. D.; Keefer, C. J.; Goodman, H. A.; Song, S. Y.; Yang, L.; Pietenpol, J. A. Negative regulation of Wee1 expression and Cdc2 phosphorylation during p53-mediated growth arrest and apoptosis. Cancer Res, 1998, 58, 3231-3236.
116. Chen, G.; Shi, L.; Litchfield, D. W.; Greenberg, A. H. Rescue from granzyme B-induced apoptosis by Wee1 kinase. J. Exp. Med., 1995, 181, 2295-2300.
117. Wang, Yuli; Li, Jun; Booher, Robert N.; Kraker, Alan; Lawrence, Theodore; Leopold, Wilbur R.; Sun, Yi. Radiosensitization of p53 Mutant Cells by PD0166285, a Novel G2 Checkpoint Abrogator. Cancer Res, 2001, 61, 8211-8217.
118. Hirai, H.; Iwasawa, Y.; Okada, M.; Arai, T.; Nishibata, T.; Kobayashi, M.; Kimura, T.; Kaneko, N.; Ohtani, J.; Yamanaka, K.; Itadani, H.; Takahashi-Suzuki, I.; Fukasawa, K.; Oki, H.; Nambu, T.; Jiang, J.; Sakai, T.; Arakawa, H.; Sakamoto, T.; Sagara, T.; Yoshizumi, T.; Mizuarai, S.; Kotani, H. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther, 2009, 8, 2992-3000.
119. Stobbe, C. C.; Park, S. J.; Chapman, J. D. The radiation hypersensitivity of cells at mitosis. Int J Radiat Biol, 2002, 78, 1149-1157.
120. Dewey, W. C.; Westra, A.; Miller, H. H.; Nagasawa, H. Heat-induced lethality and chromosomal damage in synchronized Chinese hamster cells treated with 5-bromodeoxyuridine. Int J Radiat Biol Relat Stud Phys Chem Med, 1971, 20, 505-520.
121. Westra, A.; Dewey, W. C. Variation in sensitivity to heat shock during the cell-cycle of Chinese hamster cells in vitro. Int J Radiat Biol Relat Stud Phys Chem Med, 1971, 19, 467-477.
122. Wood, Kenneth W.; Cornwell, William D.; Jackson, Jeffrey R. Past and future of the mitotic spindle as an oncology target. Current Opinion in Pharmacology, 2001, 1, 370-377.
123. Gottesfeld, Joel M.; Forbes, Douglass J. Mitotic repression of the transcriptional machinery. Trends in Biochemical Sciences, 1997, 22, 197-202.
124. Margolis, R. L.; Lohez, O. D.; Andreassen, P. R. G1 tetraploidy checkpoint and the suppression of tumorigenesis. J Cell Biochem, 2003, 88, 673-683.
125. Rieder, C. L.; Maiato, H. Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev Cell, 2004, 7, 637-651.
126. Jallepalli, P. V.; Lengauer, C. Chromosome segregation and cancer: cutting through the mystery. Nature Reviews. Cancer, 2001, 1, 109-117.
127. Jordan, Mary Ann; Wilson, Leslie. Microtubules as a target for anticancer drugs. Nature Reviews. Cancer, 2004, 4, 253-265.
128. Malumbres, M. Therapeutic opportunities to control tumor cell cycles. Clin Transl Oncol, 2006, 8, 399-408.
129. Sudo, Tamotsu; Nitta, Masayuki; Saya, Hideyuki; Ueno, Naoto T. Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Research, 2004, 64, 2502-2508.
130. Perez De Castro, I.; De Carcer, G.; Malumbres, M. A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy. Carcinogenesis, 2007, 28, 899-912.
131. cdc2 and cyclin D1 protein expression in prostate adenocarcinoma. Cancer, 1997, 80, 753-763.
132. Soria, Jean-Charles; Jang, Se Jin; Khuri, Fadlo R.; Hassan, Khaled; Liu, Diane; Hong, Waun Ki; Mao, Li. Overexpression of Cyclin B1 in Early-Stage Non-Small Cell Lung Cancer and Its Clinical Implication. Cancer Res, 2000, 60, 4000-4004.
133. Shinsuke Takeno, Tsuyoshi Noguchi, Ryuichi Kikuchi, Yuzo Uchida, Shigeo Yokoyama, Wolfram Müller. Prognostic value of cyclin B1 in patients with esophageal squamous cell carcinoma. Cancer, 2002, 94, 2874-2881.
134. 3 integrin expression up-regulates cdc2, which modulates cell migration. J. Cell Biol., 2003, 161, 817-826.
135. Payton, Marc; Chung, Grace; Yakowec, Peter; Wong, Andrew; Powers, Dave; Xiong, Ling; Zhang, Nancy; Leal, Juan; Bush, Tammy L.; Santora, Vincent; Askew, Ben; Tasker, Andrew; Radinsky, Robert; Kendall, Richard; Coats, Steve. Discovery and Evaluation of Dual CDK1 and CDK2 Inhibitors. Cancer Res, 2006, 66, 4299-4308.
136. Brachwitz, K.; Voigt, B.; Meijer, L.; Lozach, O.; Schachtele, C.; Molnar, J.; Hilgeroth, A. Evaluation of the first cytostatically active 1-aza-9-oxafluorenes as novel selective CDK1 inhibitors with P-glycoprotein modulating properties. J Med Chem, 2003, 46, 876-879.
137. Vassilev, Lyubomir T.; Tovar, Christian; Chen, Shaoqing; Knezevic, Dejan; Zhao, Xiaolan; Sun, Hongmao; Heimbrook, David C.; Chen, Li. Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. PNAS, 2006, 103, 10660-10665.
138. Malumbres, M.; Pevarello, P.; Barbacid, M.; Bischoff, J. R. CDK inhibitors in cancer therapy: what is next? Trends Pharmacol Sci, 2008, 29, 16-21.
139. Al-Sha'er, M. A.; Taha, M. O. Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay. Eur J Med Chem, 2010, 45, 4316-4330.
140. Goga, A.; Yang, D.; Tward, A. D.; Morgan, D. O.; Bishop, J. M. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat Med, 2007, 13, 820-827.
141. Carmena, M.; Earnshaw, W. C. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol, 2003, 4, 842-854.
142. Meraldi, P.; Honda, R.; Nigg, E. A. Aurora kinases link chromosome segregation and cell division to cancer susceptibility. Curr Opin Genet Dev, 2004, 14, 29-36.
143. Keen, N.; Taylor, S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer, 2004, 4, 927-936.
144. Anand, S.; Penrhyn-Lowe, S.; Venkitaraman, A. R. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell, 2003, 3, 51-62.
145. Bischoff, J. R.; Anderson, L.; Zhu, Y.; Mossie, K.; Ng, L.; Souza, B.; Schryver, B.; Flanagan, P.; Clairvoyant, F.; Ginther, C.; Chan, C. S.; Novotny, M.; Slamon, D. J.; Plowman, G. D. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. Embo J, 1998, 17, 3052-3065.
146. Meraldi, P.; Honda, R.; Nigg, E. A. Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53-/-cells. Embo J, 2002, 21, 483-492.
147. Ouchi, Mutsuko; Fujiuchi, Nobuko; Sasai, Kaori; Katayama, Hiroshi; Minamishima, Yohji A.; Ongusaha, Pat P.; Deng, Chuxia; Sen, Subrata; Lee, Sam W.; Ouchi, Toru. BRCA1 Phosphorylation by Aurora-A in the Regulation of G2 to M Transition. J. Biol. Chem., 2004, 279, 19643-19648.
148. Toji, S.; Yabuta, N.; Hosomi, T.; Nishihara, S.; Kobayashi, T.; Suzuki, S.; Tamai, K.; Nojima, H. The centrosomal protein Lats2 is a phosphorylation target of Aurora-A kinase. Genes Cells, 2004, 9, 383-397.
149. Li, Jonathan J.; Li, Sara Antonia. Mitotic kinases: The key to duplication, segregation, and cytokinesis errors, chromosomal instability, and oncogenesis. Pharmacology & Therapeutics, 2006, 111, 974-984.
150. Altieri, D. C. Survivin and apoptosis control. Adv Cancer Res, 2003, 88, 31-52.
151. Li, Xiangyu; Sakashita, Gyosuke; Matsuzaki, Hideki; Sugimoto, Kenji; Kimura, Keiji; Hanaoka, Fumio; Taniguchi, Hisaaki; Furukawa, Koichi; Urano, Takeshi. Direct Association with Inner Centromere Protein (INCENP) Activates the Novel Chromosomal Passenger Protein, Aurora-C. J. Biol. Chem., 2004, 279, 47201-47211.
152. Kaori Sasai, Hiroshi Katayama, David L. Stenoien, Satoshi Fujii, Reiko Honda, Masashi Kimura, Yukio Okano, Masaaki Tatsuka, Fumio Suzuki, Erich A. Nigg, William C. Earnshaw, William R. Brinkley, Subrata Sen Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells. Cell Motility and the Cytoskeleton, 2004, 59, 249-263.
153. Doggrell, S. A. Dawn of Aurora kinase inhibitors as anticancer drugs. Expert Opin Investig Drugs, 2004, 13, 1199-1201.
154. Hauf, Silke; Cole, Richard W.; Laterra, Sabrina; Zimmer, Christine; Schnapp, Gisela; Walter, Rainer; Heckel, Armin; Van Meel, Jacques; Rieder, Conly L.; Peters, Jan-Michael. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J. Cell Biol., 2003, 161, 281-294.
155. Gadea, Bedrick B.; Ruderman, Joan V. Aurora Kinase Inhibitor ZM447439 Blocks Chromosome-induced Spindle Assembly, the Completion of Chromosome Condensation, and the Establishment of the Spindle Integrity Checkpoint in Xenopus Egg Extracts. Mol. Biol. Cell, 2005, 16, 1305-1318.
156. Harrington, Elizabeth A.; Bebbington, David; Moore, Jeff; Rasmussen, Richele K.; Ajose-Adeogun, Abi O.; Nakayama, Tomoko; Graham, Joanne A.; Demur, Cecile; Hercend, Thierry; Diu-Hercend, Anita; Su, Michael; Golec, Julian M. C.; Miller, Karen M. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med, 2004, 10, 262-267.
157. Soncini, Chiara; Carpinelli, Patrizia; Gianellini, Laura; Fancelli, Daniele; Vianello, Paola; Rusconi, Luisa; Storici, Paola; Zugnoni, Paola; Pesenti, Enrico; Croci, Valter; Ceruti, Roberta; Giorgini, Maria Laura; Cappella, Paolo; Ballinari, Dario; Sola, Francesco; Varasi, Mario; Bravo, Rodrigo; Moll, Jurgen. PHA-680632, a Novel Aurora Kinase Inhibitor with Potent Antitumoral Activity. Clin Cancer Res, 2006, 12, 4080-4089.
158. Emanuel, Stuart; Rugg, Catherine A.; Gruninger, Robert H.; Lin, Ronghui; Fuentes-Pesquera, Angel; Connolly, Peter J.; Wetter, Steven K.; Hollister, Beth; Kruger, Walter W.; Napier, Cheryl; Jolliffe, Linda; Middleton, Steven A. The In vitro and In vivo Effects of JNJ-7706621: A Dual Inhibitor of Cyclin-Dependent Kinases and Aurora Kinases. Cancer Res, 2005, 65, 9038-9046.
159. Lens, S. M.; Voest, E. E.; Medema, R. H. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer, 2010, 10, 825-841.
160. Katayama, H.; Sen, S. Aurora kinase inhibitors as anticancer molecules. Biochim Biophys Acta, 2010, 1799, 829-839.
161. Carpinelli, P.; Moll, J. Aurora kinases and their inhibitors: more than one target and one drug. Adv Exp Med Biol, 2008, 610, 54-73.
162. Eckerdt, Frank; Yuan, Juping; Strebhardt, Klaus. Polo-like kinases and oncogenesis. Oncogene, 2005, 24, 267-276.
163. Takai, Noriyuki; Hamanaka, Ryoji; Yoshimatsu, Jun; Miyakawa, Isao. Polo-like kinases (Plks) and cancer. Oncogene, 2005, 24, 287-291.
164. Strebhardt, K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov, 9, 643-660.
165. De Carcer, G.; Manning, G.; Malumbres, M. From Plk1 to Plk5: functional evolution of polo-like kinases. Cell Cycle, 10, 2255-2262.
166. Barr, F. A.; Sillje, H. H.; Nigg, E. A. Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol, 2004, 5, 429-440.
167. Strebhardt, Klaus; Ullrich, Axel. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer, 2006, 6, 321-330.
168. Stevenson, C. S.; Capper, E. A.; Roshak, A. K.; Marquez, B.; Grace, K.; Gerwick, W. H.; Jacobs, R. S.; Marshall, L. A. Scytonemin--a marine natural product inhibitor of kinases key in hyperproliferative inflammatory diseases. Inflamm Res, 2002, 51, 112-114.
169. Liu, Yongsheng; Shreder, Kevin R.; Gai, Wenzhi; Corral, Sergio; Ferris, Douglas K.; Rosenblum, Jonathan S. Wortmannin, a Widely Used Phosphoinositide 3-Kinase Inhibitor, also Potently Inhibits Mammalian Polo-like Kinase. Chemistry & Biology, 2005, 12, 99-107.
170. Santamaria, A.; Neef, R.; Eberspacher, U.; Eis, K.; Husemann, M.; Mumberg, D.; Prechtl, S.; Schulze, V.; Siemeister, G.; Wortmann, L.; Barr, F. A.; Nigg, E. A. Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis. Mol Biol Cell, 2007, 18, 4024-4036.
171. G. Munzert, S. Steinbild, A. Frost, S. Hedborn, J. Rentschler, R. Kaiser, D. Trommeshauser, M. Hoffmann, M. Steegmaier, K. Mross. In ASCO Annual Meeting Proceedings Journal of Clinical Oncology, 2006; Vol. Vol 24, No. 18S (June 20 Supplement).
172. Hofheinz, R.; Hochhaus, A.; Al-Batran, S.; Nanci, A.; Reichardt, V.; Trommeshauser, D.; Hoffmann, M.; Steegmaier, M.; Munzert, G.; Jager, E. A phase I repeated dose escalation study of the Polo-like kinase 1 inhibitor BI 2536 in patients with advanced solid tumours. J Clin Oncol (Meeting Abstracts), 2006, 24, 2038-.
173. Rudolph, D.; Steegmaier, M.; Hoffmann, M.; Grauert, M.; Baum, A.; Quant, J.; Haslinger, C.; Garin-Chesa, P.; Adolf, G. R. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res, 2009, 15, 3094-3102.
174. Stevenson, Christopher S.; Capper, Elizabeth A.; Roshak, Amy K.; Marquez, Brian; Eichman, Chris; Jackson, Jeffrey R.; Mattern, Michael; Gerwick, William H.; Jacobs, Robert S.; Marshall, Lisa A. The Identification and Characterization of the Marine Natural Product Scytonemin as a Novel Antiproliferative Pharmacophore. J Pharmacol Exp Ther, 2002, 303, 858-866.
175. Perez De Castro, I.; De Carcer, G.; Montoya, G.; Malumbres, M. Emerging cancer therapeutic opportunities by inhibiting mitotic kinases. Curr Opin Pharmacol, 2008, 8, 375-383.
176. Liao, C.; Park, J. E.; Bang, J. K.; Nicklaus, M. C.; Lee, K. S. Exploring Potential Binding Modes of Small Drug-like Molecules to the Polo-Box Domain of Human Polo-like Kinase 1. ACS Med Chem Lett, 2010, 1, 110-114.
177. Lee, K. S.; Idle, J. R. Pinning down the polo-box domain. Chem Biol, 2008, 15, 415-416.
178. Li, L.; Wang, X.; Chen, J.; Ding, H.; Zhang, Y.; Hu, T. C.; Hu, L. H.; Jiang, H. L.; Shen, X. The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation. Acta Pharmacol Sin, 2009, 30, 1443-1453.
179. Reindl, W.; Yuan, J.; Kramer, A.; Strebhardt, K.; Berg, T. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. Chem Biol, 2008, 15, 459-466.
180. Reindl, W.; Yuan, J.; Kramer, A.; Strebhardt, K.; Berg, T. A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis. Chembiochem, 2009, 10, 1145-1148.
181. Gumireddy, Kiranmai; Reddy, M. V. Ramana; Cosenza, Stephen C.; Nathan, R. Boomi; Baker, Stacey J.; Papathi, Nabisa; Jiang, Jiandong; Holland, James; Reddy, E. Premkumar. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell, 2005, 7, 275-286.
182. Habedanck, R.; Stierhof, Y. D.; Wilkinson, C. J.; Nigg, E. A. The Polo kinase Plk4 functions in centriole duplication. Nat Cell Biol, 2005, 7, 1140-1146.
183. Swallow, Carol J.; Ko, Michael A.; Siddiqui, Najeeb U.; Hudson, John W.; Dennis, James W. Sak//Plk4 and mitotic fidelity. Oncogene, 2005, 24, 306-312.
184. Ko, Michael A.; Rosario, Carla O.; Hudson, John W.; Kulkarni, Sarang; Pollett, Aaron; Dennis, James W.; Swallow, Carol J. Plk4 haploinsufficiency causes mitotic infidelity and carcinogenesis. Nat Genet, 2005, 37, 883-888.
185. De Carcer, G.; Escobar, B.; Higuero, A. M.; Garcia, L.; Anson, A.; Perez, G.; Mollejo, M.; Manning, G.; Melendez, B.; Abad-Rodriguez, J.; Malumbres, M. Plk5, a polo box domain-only protein with specific roles in neuron differentiation and glioblastoma suppression. Mol Cell Biol, 2011, 31, 1225-1239.
186. O'connell, Matthew J.; Krien, Michael J. E.; Hunter, Tony. Never say never. The NIMA-related protein kinases in mitotic control. Trends in Cell Biology, 2003, 13, 221-228.
187. Quarmby, L. M.; Mahjoub, M. R. Caught Nek-ing: cilia and centrioles. J Cell Sci, 2005, 118, 5161-5169.
188. Hayward, Daniel G.; Fry, Andrew M. Nek2 kinase in chromosome instability and cancer. Cancer Letters, 2006, 237, 155-166.
189. Fry, A. M. The Nek2 protein kinase: a novel regulator of centrosome structure. Oncogene, 2002, 21, 6184-6194.
190. Ha Kim, Yong; Yeol Choi, Jun; Jeong, Yeontae; Wolgemuth, Debra J.; Rhee, Kunsoo. Nek2 Localizes to Multiple Sites in Mitotic Cells, Suggesting Its Involvement in Multiple Cellular Functions during the Cell Cycle. Biochemical and Biophysical Research Communications, 2002, 290, 730-736.
191. Lou, Yang; Yao, Jianhui; Zereshki, Arzhang; Dou, Zhen; Ahmed, Kashif; Wang, Hongmei; Hu, Junbin; Wang, Yuzhen; Yao, Xuebiao. NEK2A interacts with MAD1 and possibly functions as a novel integrator of the spindle checkpoint signaling. The Journal Of Biological Chemistry, 2004, 279, 20049-20057.
192. Chen, Yumay; Riley, Daniel J.; Zheng, Lei; Chen, Phang-Lang; Lee, Wen-Hwa. Phosphorylation of the Mitotic Regulator Protein Hec1 by Nek2 Kinase Is Essential for Faithful Chromosome Segregation. J. Biol. Chem., 2002, 277, 49408-49416.
193. Chen, Jian; Li, Li; Zhang, Yuanyuan; Yang, Huirong; Wei, Youheng; Zhang, Lin; Liu, Xianghua; Yu, Long. Interaction of Pin1 with Nek6 and characterization of their expression correlation in Chinese hepatocellular carcinoma patients. Biochemical and Biophysical Research Communications, 2006, 341, 1059-1065.
194. Liu, Shanming; Lu, Weining; Obara, Tomoko; Kuida, Shiei; Lehoczky, Jennifer; Dewar, Ken; Drummond, Iain A.; Beier, David R. A defect in a novel Nek-family kinase causes cystic kidney disease in the mouse and in zebrafish. Development (Cambridge, England), 2002, 129, 5839-5846.
195. Bowers, Alex J.; Boylan, John F. Nek8, a NIMA family kinase member, is overexpressed in primary human breast tumors. Gene, 2004, 328, 135-142.
196. Whelligan, D. K.; Solanki, S.; Taylor, D.; Thomson, D. W.; Cheung, K. M.; Boxall, K.; Mas-Droux, C.; Barillari, C.; Burns, S.; Grummitt, C. G.; Collins, I.; Van Montfort, R. L.; Aherne, G. W.; Bayliss, R.; Hoelder, S. Aminopyrazine inhibitors binding to an unusual inactive conformation of the mitotic kinase Nek2: SAR and structural characterization. J Med Chem, 2010, 53, 7682-7698.
197. Jablonski, S. A.; Liu, S. T.; Yen, T. J. Targeting the kinetochore for mitosis-specific inhibitors. Cancer Biol Ther, 2003, 2, 236-241.
198. Cahill, Daniel P.; Lengauer, Christoph; Yu, Jian; Riggins, Gregory J.; Willson, James K. V.; Markowitz, Sanford D.; Kinzler, Kenneth W.; Vogelstein, Bert. Mutations of mitotic checkpoint genes in human cancers. Nature, 1998, 392, 300-303.
199. Ru, H. Y.; Chen, R. L.; Lu, W. C.; Chen, J. H. hBUB1 defects in leukemia and lymphoma cells. Oncogene, 2002, 21, 4673-4679.
200. Akihiko Gemma, Masahiro Seike, Yoko Seike, Kazutsugu Uematsu, Suguru Hibino, Futosi Kurimoto, Akinobu Yoshimura, Masahiko Shibuya, Curtis C. Harris, Shoji Kudoh. Somatic mutation of the hBUB1 mitotic checkpoint gene in primary lung cancer. Genes, Chromosomes and Cancer, 2000, 29, 213-218.
201. Hempen, P. M.; Kurpad, H.; Calhoun, E. S.; Abraham, S.; Kern, S. E. A double missense variation of the BUB1 gene and a defective mitotic spindle checkpoint in the pancreatic cancer cell line Hs766T. Hum Mutat, 2003, 21, 445.
202. Hanks, Sandra; Coleman, Kim; Reid, Sarah; Plaja, Alberto; Firth, Helen; Fitzpatrick, David; Kidd, Alexa; Mehes, Karoly; Nash, Richard; Robin, Nathanial; Shannon, Nora; Tolmie, John; Swansbury, John; Irrthum, Alexandre; Douglas, Jenny; Rahman, Nazneen. Constitutional aneuploidy and cancer predisposition caused by biallelic mutations in BUB1B. Nat Genet, 2004, 36, 1159-1161.
203. Matsuura, S.; Matsumoto, Y.; Morishima, K.; Izumi, H.; Matsumoto, H.; Ito, E.; Tsutsui, K.; Kobayashi, J.; Tauchi, H.; Kajiwara, Y.; Hama, S.; Kurisu, K.; Tahara, H.; Oshimura, M.; Komatsu, K.; Ikeuchi, T.; Kajii, T. Monoallelic BUB1B mutations and defective mitotic-spindle checkpoint in seven families with premature chromatid separation (PCS) syndrome. Am J Med Genet A, 2006, 140, 358-367.
204. Kalitsis, P.; Earle, E.; Fowler, K. J.; Choo, K. H. Bub3 gene disruption in mice reveals essential mitotic spindle checkpoint function during early embryogenesis. Genes Dev, 2000, 14, 2277-2282.
205. Baker, D. J.; Jeganathan, K. B.; Cameron, J. D.; Thompson, M.; Juneja, S.; Kopecka, A.; Kumar, R.; Jenkins, R. B.; De Groen, P. C.; Roche, P.; Van Deursen, J. M. BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility in mice. Nat Genet, 2004, 36, 744-749.
206. Kalitsis, P.; Fowler, K. J.; Griffiths, B.; Earle, E.; Chow, C. W.; Jamsen, K.; Choo, K. H. Increased chromosome instability but not cancer predisposition in haploinsufficient Bub3 mice. Genes Chromosomes Cancer, 2005, 44, 29-36.
207. Baker, D. J.; Jeganathan, K. B.; Malureanu, L.; Perez-Terzic, C.; Terzic, A.; Van Deursen, J. M. Early aging-associated phenotypes in Bub3/Rae1 haploinsufficient mice. J Cell Biol, 2006, 172, 529-540.
208. Kops, G. J.; Foltz, D. R.; Cleveland, D. W. Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. Proc Natl Acad Sci U S A, 2004, 101, 8699-8704.
209. Fisk, H. A.; Mattison, C. P.; Winey, M. A field guide to the Mps1 family of protein kinases. Cell Cycle, 2004, 3, 439-442.
210. Stucke, V. M.; Sillje, H. H. W.; Arnaud, L.; Nigg, E. A. Human Mps1 kinase is required for the spindle assembly checkpoint but not for centrosome duplication. Embo Journal, 2002, 21, 1723-1732.
211. Palframan, W. J.; Meehl, J. B.; Jaspersen, S. L.; Winey, M.; Murray, A. W. Anaphase inactivation of the spindle checkpoint. Science, 2006, 313, 680-684.
212. Stucke, V. M.; Baumann, C.; Nigg, E. A. Kinetochore localization and microtubule interaction of the human spindle checkpoint kinase Mps1. Chromosoma, 2004, 113, 1-15.
213. Wei, Jen-Hsuan; Chou, Yi-Fan; Ou, Yi-Hung; Yeh, Yen-Hsiu; Tyan, Shiaw-Wei; Sun, Te-Ping; Shen, Chen-Yang; Shieh, Sheau-Yann. TTK/hMps1 Participates in the Regulation of DNA Damage Checkpoint Response by Phosphorylating CHK2 on Threonine 68. J. Biol. Chem., 2005, 280, 7748-7757.
214. Poss, K. D.; Nechiporuk, A.; Stringer, K. F.; Lee, C.; Keating, M. T. Germ cell aneuploidy in zebrafish with mutations in the mitotic checkpoint gene mps1. Genes Dev, 2004, 18, 1527-1532.
215. Dorer, Russell K.; Zhong, Sheng; Tallarico, John A.; Wong, Wing Hung; Mitchison, Timothy J.; Murray, Andrew W. A Small-Molecule Inhibitor of Mps1 Blocks the Spindle-Checkpoint Response to a Lack of Tension on Mitotic Chromosomes. Current Biology, 2005, 15, 1070-1076.
216. Schmidt, M.; Budirahardja, Y.; Klompmaker, R.; Medema, R. H. Ablation of the spindle assembly checkpoint by a compound targeting Mps1. EMBO Rep, 2005, 6, 866-872.
217. Kwiatkowski, N.; Jelluma, N.; Filippakopoulos, P.; Soundararajan, M.; Manak, M. S.; Kwon, M.; Choi, H. G.; Sim, T.; Deveraux, Q. L.; Rottmann, S.; Pellman, D.; Shah, J. V.; Kops, G. J.; Knapp, S.; Gray, N. S. Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function. Nat Chem Biol, 2010, 6, 359-368.
218. Santaguida, S.; Tighe, A.; D'alise, A. M.; Taylor, S. S.; Musacchio, A. Dissecting the role of MPS1 in chromosome biorientation and the spindle checkpoint through the small molecule inhibitor reversine. J Cell Biol, 2010, 190, 73-87.
219. Colombo, R.; Caldarelli, M.; Mennecozzi, M.; Giorgini, M. L.; Sola, F.; Cappella, P.; Perrera, C.; Depaolini, S. R.; Rusconi, L.; Cucchi, U.; Avanzi, N.; Bertrand, J. A.; Bossi, R. T.; Pesenti, E.; Galvani, A.; Isacchi, A.; Colotta, F.; Donati, D.; Moll, J. Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase. Cancer Res, 2010, 70, 10255-10264.
220. Schwartz, G. K.; Shah, M. A. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol, 2005, 23, 9408-9421.
221. Dai, Jun; Sultan, Sammy; Taylor, Stephen S.; Higgins, Jonathan M. G. The kinase haspin is required for mitotic histone H3 Thr 3 phosphorylation and normal metaphase chromosome alignment. Genes Dev., 2005, 19, 472-488.
222. Walter, S. A.; Cutler, R. E., Jr.; Martinez, R.; Gishizky, M.; Hill, R. J. Stk10, a new member of the polo-like kinase kinase family highly expressed in hematopoietic tissue. J Biol Chem, 2003, 278, 18221-18228.
223. Ellinger-Ziegelbauer, H.; Karasuyama, H.; Yamada, E.; Tsujikawa, K.; Todokoro, K.; Nishida, E. Ste20-like kinase (SLK), a regulatory kinase for polo-like kinase (Plk) during the G2/M transition in somatic cells. Genes Cells, 2000, 5, 491-498.
224. Du, J.; Widlund, H. R.; Horstmann, M. A.; Ramaswamy, S.; Ross, K.; Huber, W. E.; Nishimura, E. K.; Golub, T. R.; Fisher, D. E. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell, 2004, 6, 565-576.
225. Rhodes, D. R.; Yu, J.; Shanker, K.; Deshpande, N.; Varambally, R.; Ghosh, D.; Barrette, T.; Pandey, A.; Chinnaiyan, A. M. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia, 2004, 6, 1-6.
226. Wolfel, T.; Hauer, M.; Schneider, J.; Serrano, M.; Wolfel, C.; Klehmann-Hieb, E.; De Plaen, E.; Hankeln, T.; Meyer Zum Buschenfelde, K. H.; Beach, D. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science, 1995, 269, 1281-1284.
227. Zuo, L.; Weger, J.; Yang, Q.; Goldstein, A. M.; Tucker, M. A.; Walker, G. J.; Hayward, N.; Dracopoli, N. C. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nature Genetics, 1996, 12, 97-99.
228. Lu, H.; Schulze-Gahmen, U. Toward Understanding the Structural Basis of Cyclin-Dependent Kinase 6 Specific Inhibition. J. Med. Chem., 2006, 49, 3826-3831.
229. Dash, B. C.; El-Deiry, W. S. Cell cycle checkpoint control mechanisms that can be disrupted in cancer. Methods Mol Biol, 2004, 280, 99-161.
230. Xianglin Wu, Xiangyang Dong Wanguo Liu Junjie Chen. Characterization of CHEK2 mutations in prostate cancer. Human Mutation, 2006, 27, 742-747.
231. Meijers-Heijboer H, Van Den Ouweland a, Klijn J, Wasielewski M, De Snoo a, Oldenburg R, Hollestelle a, Houben M, Crepin E, Van Veghel-Plandsoen M, Elstrodt F, Van Duijn C, Bartels C, Meijers C, Schutte M, Mcguffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans Dg, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang Hx, Szabo C, Devilee P, Goldgar D, Futreal Pa, Nathanson Kl, Weber B, Rahman N, Stratton Mr,. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet, 2002, 31, 55-59.
232. Cybulski, Cezary; Huzarski, Tomasz; Gorski, Bohdan; Masojc, Bartlomiej; Mierzejewski, Marek; Debniak, Tadeusz; Gliniewicz, Bartlomiej; Matyjasik, Joanna; Zlowocka, Elzbieta; Kurzawski, Grzegorz; Sikorski, Andrzej; Posmyk, Michal; Szwiec, Marek; Czajka, Ryszard; Narod, Steven A.; Lubinski, Jan. A Novel Founder CHEK2 Mutation is Associated with Increased Prostate Cancer Risk. Cancer Res, 2004, 64, 2677-2679.
233. Simizu, Siro; Osada, Hiroyuki. Mutations in the Plk gene lead to instability of Plk protein in human tumour cell lines. Nat Cell Biol, 2000, 2, 852-854.
234. Shinya Matsuura, Yoshiyuki Matsumoto, Ken-Ichi Morishima, Hideki Izumi, Hiroshi Matsumoto, Emi Ito, Keisuke Tsutsui, Junya Kobayashi, Hiroshi Tauchi, Yoshinori Kajiwara, Seiji Hama, Kaoru Kurisu, Hidetoshi Tahara, Mitsuo Oshimura, Kenshi Komatsu, Tatsuro Ikeuchi, Tadashi Kajii. Monoallelic BUB1B mutations and defective mitotic-spindle checkpoint in seven families with premature chromatid separation (PCS) syndrome. American Journal of Medical Genetics Part A, 2006, 140A, 358-367.
235. Fukuoka, K.; Usuda, J.; Iwamoto, Y.; Fukumoto, H.; Nakamura, T.; Yoneda, T.; Narita, N.; Saijo, N.; Nishio, K. Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells. Invest New Drugs, 2001, 19, 219-227.
236. Pevarello, P.; Brasca, M. G.; Orsini, P.; Traquandi, G.; Longo, A.; Nesi, M.; Orzi, F.; Piutti, C.; Sansonna, P.; Varasi, M.; Cameron, A.; Vulpetti, A.; Roletto, F.; Alzani, R.; Ciomei, M.; Albanese, C.; Pastori, W.; Marsiglio, A.; Pesenti, E.; Fiorentini, F.; Bischoff, J. R.; Mercurio, C. 3-Aminopyrazole Inhibitors of CDK2/Cyclin A as Antitumor Agents. 2. Lead Optimization. J. Med. Chem., 2005, 48, 2944-2956.
237. Meijer, L.; Thunnissen, A. M.; White, A. W.; Garnier, M.; Nikolic, M.; Tsai, L. H.; Walter, J.; Cleverley, K. E.; Salinas, P. C.; Wu, Y. Z.; Biernat, J.; Mandelkow, E. M.; Kim, S. H.; Pettit, G. R. Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent. Chem Biol, 2000, 7, 51-63.
238. Arris, C. E.; Boyle, F. T.; Calvert, A. H.; Curtin, N. J.; Endicott, J. A.; Garman, E. F.; Gibson, A. E.; Golding, B. T.; Grant, S.; Griffin, R. J.; Jewsbury, P.; Johnson, L. N.; Lawrie, A. M.; Newell, D. R.; Noble, M. E. M.; Sausville, E. A.; Schultz, R.; Yu, W. Identification of Novel Purine and Pyrimidine Cyclin-Dependent Kinase Inhibitors with Distinct Molecular Interactions and Tumor Cell Growth Inhibition Profiles. J. Med. Chem., 2000, 43, 2797-2804.
239. Mesguiche, Veronique; Parsons, Rachel J.; Arris, Christine E.; Bentley, Johanne; Boyle, F. Thomas; Curtin, Nicola J.; Davies, Thomas G.; Endicott, Jane A.; Gibson, Ashleigh E.; Golding, Bernard T. 4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2. Bioorganic & Medicinal Chemistry Letters, 2003, 13, 217-222.
240. Byth, Kate F.; Geh, Catherine; Forder, Cheryl L.; Oakes, Sandra E.; Thomas, Andrew P. The cellular phenotype of AZ703, a novel selective imidazo[1,2-a]pyridine cyclin-dependent kinase inhibitor. Mol Cancer Ther, 2006, 5, 655-664.
241. Cai, Dongpo; Byth, Kate F.; Shapiro, Geoffrey I. AZ703, an Imidazo[1,2-a]Pyridine Inhibitor of Cyclin-Dependent Kinases 1 and 2, Induces E2F-1-Dependent Apoptosis Enhanced by Depletion of Cyclin-Dependent Kinase 9. Cancer Res, 2006, 66, 435-444.
242. Meijer, L.; Raymond, E. Roscovitine and Other Purines as Kinase Inhibitors. From Starfish Oocytes to Clinical Trials. Acc. Chem. Res., 2003, 36, 417-425.
243. Pennati, Marzia; Campbell, Allyson J.; Curto, Maria; Binda, Mara; Cheng, Yuzhu; Wang, Lan-Zeng; Curtin, Nicola; Golding, Bernard T.; Griffin, Roger J.; Hardcastle, Ian R.; Henderson, Andrew; Zaffaroni, Nadia; Newell, David R. Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Mol Cancer Ther, 2005, 4, 1328-1337.
244. Brooks, Eric E.; Gray, Nathanael S.; Joly, Alison; Kerwar, Suresh S.; Lum, Robert; Mackman, Richard L.; Norman, Thea C.; Rosete, Jose; Rowe, Michael; Schow, Steven R.; Schultz, Peter G.; Wang, Xingbo; Wick, Michael M.; Shiffman, Dov. CVT-313, a Specific and Potent Inhibitor of CDK2 That Prevents Neointimal Proliferation. J. Biol. Chem., 1997, 272, 29207-29211.
245. Lane, Maureen E.; Yu, Bo; Rice, Audie; Lipson, Kenneth E.; Liang, Chris; Sun, Li; Tang, Cho; Mcmahon, Gerald; Pestell, Richard G.; Wadler, Scott. A Novel cdk2-selective Inhibitor, SU9516, Induces Apoptosis in Colon Carcinoma Cells. Cancer Res, 2001, 61, 6170-6177.
246. Gray, N.; Detivaud, L.; Doerig, C.; Meijer, L. ATP-site directed inhibitors of cyclin-dependent kinases. Curr Med Chem, 1999, 6, 859-875.
247. Broxterman, Henk J.; Georgopapadakou, Nafsika H. Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations. Drug Resistance Updates, 2005, 8, 183-197.
248. Soni, Rajeev; Muller, Lionel; Furet, Pascal; Schoepfer, Joseph; Stephan, Christine; Zumstein-Mecker, Sabine; Fretz, Heinz; Chaudhuri, Bhabatosh. Inhibition of Cyclin-Dependent Kinase 4 (Cdk4) by Fascaplysin, a Marine Natural Product. Biochemical and Biophysical Research Communications, 2000, 275, 877-884.
249. Mahale, Sachin; Aubry, Carine; James Wilson, A.; Jenkins, Paul R.; Marechal, Jean-Didier; Sutcliffe, Michael J.; Chaudhuri, Bhabatosh. CA224, a non-planar analogue of fascaplysin, inhibits Cdk4 but not Cdk2 and arrests cells at G0/G1 inhibiting pRB phosphorylation. Bioorganic & Medicinal Chemistry Letters, 2006, 16, 4272-4278.
250. Wang, Qizhi; Fan, Saijun; Eastman, Alan; Worland, Peter J.; Sausville, Edward A.; O'connor, Patrick M. UCN-01: a Potent Abrogator of G2 Checkpoint Function in Cancer Cells With Disrupted p53. J Natl Cancer Inst, 1996, 88, 956-965.
251. Ashwell, S.; Janetka, J. W.; Zabludoff, S. Keeping checkpoint kinases in line: new selective inhibitors in clinical trials. Expert Opin Investig Drugs, 2008, 17, 1331-1340.
252. Riesterer, O.; Matsumoto, F.; Wang, L.; Pickett, J.; Molkentine, D.; Giri, U.; Milas, L.; Raju, U. A novel Chk inhibitor, XL-844, increases human cancer cell radiosensitivity through promotion of mitotic catastrophe. Invest New Drugs, 29, 514-522.
253. Tse, A. N.; Rendahl, K. G.; Sheikh, T.; Cheema, H.; Aardalen, K.; Embry, M.; Ma, S.; Moler, E. J.; Ni, Z. J.; Lopes De Menezes, D. E.; Hibner, B.; Gesner, T. G.; Schwartz, G. K. CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo. Clin Cancer Res, 2007, 13, 591-602.
254. Von Hoff, D. D.; Taylor, C.; Rubin, S.; Cohen, J.; Garland, L. A Phase I and pharmacokinetic study of HMN-214, a novel oral polo-like kinase inhibitor, in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts), 2004, 22, 3034-.
255. Mcinnes, C.; Mazumdar, A.; Mezna, M.; Meades, C.; Midgley, C.; Scaerou, F.; Carpenter, L.; Mackenzie, M.; Taylor, P.; Walkinshaw, M.; Fischer, P. M.; Glover, D. Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance. Nat Chem Biol, 2006, 2, 608-617.
256. Beria, I.; Bossi, R. T.; Brasca, M. G.; Caruso, M.; Ceccarelli, W.; Fachin, G.; Fasolini, M.; Forte, B.; Fiorentini, F.; Pesenti, E.; Pezzetta, D.; Posteri, H.; Scolaro, A.; Re Depaolini, S.; Valsasina, B. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. Bioorg Med Chem Lett, 2011, 21, 2969-2974.
257. Lansing, T. J.; Mcconnell, R. T.; Duckett, D. R.; Spehar, G. M.; Knick, V. B.; Hassler, D. F.; Noro, N.; Furuta, M.; Emmitte, K. A.; Gilmer, T. M.; Mook, R. A., Jr.; Cheung, M. In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1. Mol Cancer Ther, 2007, 6, 450-459.
258. Nihal, M.; Stutz, N.; Schmit, T.; Ahmad, N.; Wood, G. S. Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis. Cell Cycle, 2011, 10, 1303-1311.
259. Sato, Y.; Onozaki, Y.; Sugimoto, T.; Kurihara, H.; Kamijo, K.; Kadowaki, C.; Tsujino, T.; Watanabe, A.; Otsuki, S.; Mitsuya, M.; Iida, M.; Haze, K.; Machida, T.; Nakatsuru, Y.; Komatani, H.; Kotani, H.; Iwasawa, Y. Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors. Bioorg Med Chem Lett, 2009, 19, 4673-4678.
260. Gilmartin, A. G.; Bleam, M. R.; Richter, M. C.; Erskine, S. G.; Kruger, R. G.; Madden, L.; Hassler, D. F.; Smith, G. K.; Gontarek, R. R.; Courtney, M. P.; Sutton, D.; Diamond, M. A.; Jackson, J. R.; Laquerre, S. G. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis. Cancer Res, 2009, 69, 6969-6977.
261. Garber, K. Divide and conquer: new generation of drugs targets mitosis. J Natl Cancer Inst, 2005, 97, 874-876.
262. Warner, Steven L.; Bashyam, Sridevi; Vankayalapati, Hariprasad; Bearss, David J.; Han, Haiyong; Von Hoff, Daniel D.; Hurley, Laurence H. Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach. Mol Cancer Ther, 2006, 5, 1764-1773.
263. Shakalya, Kishore; Mahadevan, Daruka; Dai, Wei. Teicher, B.A., Ed.; Humana Press, 2008, pp 243-269.
264. Carpinelli, P.; Ceruti, R.; Giorgini, M. L.; Cappella, P.; Gianellini, L.; Croci, V.; Degrassi, A.; Texido, G.; Rocchetti, M.; Vianello, P.; Rusconi, L.; Storici, P.; Zugnoni, P.; Arrigoni, C.; Soncini, C.; Alli, C.; Patton, V.; Marsiglio, A.; Ballinari, D.; Pesenti, E.; Fancelli, D.; Moll, J. PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther, 2007, 6, 3158-3168.
265. Gontarewicz, A.; Balabanov, S.; Keller, G.; Colombo, R.; Graziano, A.; Pesenti, E.; Benten, D.; Bokemeyer, C.; Fiedler, W.; Moll, J.; Brummendorf, T. H. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood, 2008, 111, 4355-4364.
266. Mclaughlin, J.; Markovtsov, V.; Li, H.; Wong, S.; Gelman, M.; Zhu, Y.; Franci, C.; Lang, D. W.; Pali, E.; Lasaga, J.; Low, C.; Zhao, F.; Chang, B.; Gururaja, T. L.; Xu, W.; Baluom, M.; Sweeny, D.; Carroll, D.; Sran, A.; Thota, S.; Parmer, M.; Romane, A.; Clemens, G.; Grossbard, E.; Qu, K.; Jenkins, Y.; Kinoshita, T.; Taylor, V.; Holland, S. J.; Argade, A.; Singh, R.; Pine, P.; Payan, D. G.; Hitoshi, Y. Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. J Cancer Res Clin Oncol, 2010, 136, 99-113.